SYNPO2L Inhibitors
SYNPO2L inhibitors pertain to a class of chemical compounds designed to selectively interact with and inhibit the function of the SYNPO2L protein. SYNPO2L, short for Synaptopodin 2-like, is a member of the synaptopodin protein family, which plays a role in the structure and function of certain cellular components. The inhibitors targeting SYNPO2L are characterized by their ability to bind to this protein and modulate its activity. The design of these inhibitors is based on the understanding of SYNPO2L's structure and the key domains that are critical for its function. By inhibiting SYNPO2L, these compounds can affect the protein's involvement in the organization of actin cytoskeleton dynamics within cells. The inhibitors are often small molecules that can penetrate cellular membranes to reach intracellular targets, interacting with SYNPO2L through non-covalent bonds such as hydrogen bonds, hydrophobic interactions, and van der Waals forces, which result in the modulation of the protein's activity.
The development of SYNPO2L inhibitors involves detailed biochemical and biophysical studies to identify the most effective compounds. Researchers use techniques such as high-throughput screening to discover molecules that exhibit inhibitory effects on SYNPO2L. Lead compounds are then optimized through medicinal chemistry to improve their selectivity and affinity for the SYNPO2L protein. The interaction between SYNPO2L inhibitors and the protein can be evaluated using various methods, including X-ray crystallography, which provides insights into the atomic-level interactions, and surface plasmon resonance, which offers information on the binding kinetics and affinity. The specificity of these inhibitors is crucial because it ensures that they interact primarily with SYNPO2L rather than other proteins, which is important for their activity profile. The ultimate goal in developing these inhibitors is to achieve a high degree of specificity and potency towards SYNPO2L while minimizing any off-target interactions with other proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin can decrease AKT signaling, which may lead to reduced synaptic plasticity and thus inhibit the functional activity of SYNPO2L, a protein associated with synapse formation and maintenance. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, which like wortmannin, can suppress AKT pathway signaling. Inhibition of this pathway can decrease downstream effects on synaptic function, potentially leading to decreased activity of SYNPO2L. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of extracellular signal-regulated kinases (ERK). Inhibition of MEK can disrupt synaptic plasticity and neurotransmission, which could indirectly lead to decreased SYNPO2L activity due to its role in the synapse. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, similar to PD98059, inhibits MEK1 and MEK2, which may lead to reduced ERK phosphorylation and activity. This can interfere with synaptic plasticity and potentially diminish SYNPO2L's involvement in synaptic structural stabilization. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. The p38 MAPK pathway is involved in inflammatory responses and synaptic plasticity. Inhibition of this pathway can affect neuronal function and potentially decrease SYNPO2L activity, which is linked to synaptic structure. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK signaling is implicated in neuronal plasticity and apoptosis. By inhibiting JNK, SP600125 may indirectly decrease SYNPO2L's function related to synapse formation and maintenance. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $308.00 | 5 | |
NF449 is a potent and selective inhibitor of the P2X1 purinergic receptor. P2X receptors are involved in calcium signaling in neurons, and their inhibition could affect neurotransmission and thereby reduce the functional activity of SYNPO2L at the synapses. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). CaMKII is crucial for synaptic plasticity. By inhibiting CaMKII, KN-93 may impact synaptic strength and structure, potentially leading to decreased SYNPO2L activity. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. By chelating intracellular calcium, it can attenuate calcium-dependent signaling pathways, which may lead to alterations in synaptic plasticity and a potential decrease in SYNPO2L activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator but can act as a protein synthesis inhibitor. By inhibiting protein synthesis, it can prevent the expression of synaptic proteins, potentially reducing the functional activity of SYNPO2L. | ||||||